Protocol for production and expression of chimeric bovine-human monoclonal antibodies
- PMID: 36595963
- PMCID: PMC9763940
- DOI: 10.1016/j.xpro.2022.101911
Protocol for production and expression of chimeric bovine-human monoclonal antibodies
Abstract
We describe herein a protocol for production of chimeric bovine-human monoclonal antibodies (mAbs) from vaccinated cows. The genes of HIV-1-specific single B cells are amplified by reverse transcription-polymerase chain reaction (RT-PCR), cloned into human expression vectors, and expressed in human cell lines. This protocol provides an efficient step-by-step methodology to produce HIV-1 chimeric mAbs and could be widely adapted for other antigens. For complete details on the use and execution of this protocol, please refer to Heydarchi et al. (2022).1.
Keywords: Antibody; Health Sciences; Immunology; Microbiology; Molecular Biology; Single Cell.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests B.H. and D.F.J.P. are inventors on a corresponding patent from the University of Melbourne: HIV-1 antibodies PCT/AU2021/050593.
Figures
References
-
- Heydarchi B., Fong D.S., Gao H., Salazar-Quiroz N.A., Edwards J.M., Gonelli C.A., Grimley S., Aktepe T.E., Mackenzie C., Wales W.J., et al. Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell Rep. Med. 2022;3:100635. doi: 10.1016/j.xcrm.2022.100635. - DOI - PMC - PubMed
-
- Heydarchi B., Center R.J., Bebbington J., Cuthbertson J., Gonelli C., Khoury G., Mackenzie C., Lichtfuss M., Rawlin G., Muller B., Purcell D. Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env. mAbs. 2017;9:550–566. doi: 10.1080/19420862.2016.1270491. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
